Let's break down Pfizer Ltd. (PFIZER) — from its financial performance to how the market is valuing the stock.
Pfizer Revenue Trend
Pfizer Ltd.'s top line grew 10.4% to ₹2,520 Cr in FY2026, compared to ₹2,281 Cr in FY2025.
On a 10-year view, revenue grew from ₹2,017 Cr to ₹2,520 Cr at a 2.2% CAGR — slow growth that may signal a maturing business.
Pfizer Ltd. is a mid-sized pharmaceuticals company by revenue, with a top line of ₹2,520 Cr.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹2,520 Cr | +10.4% |
| FY2025 | ₹2,281 Cr | +4.0% |
| FY2024 | ₹2,193 Cr | -9.6% |
| FY2023 | ₹2,425 Cr | -7.1% |
| FY2022 | ₹2,611 Cr | — |
View Pfizer Ltd.'s full 10-year revenue trend with CAGR analysis →
Pfizer Profitability
Pfizer Ltd. saw net profit contract 5.9% to ₹722 Cr in FY2026, down from ₹768 Cr in FY2025.
Net margin slipped from 33.6% to 28.7% in FY2026 — a sign of thinning profitability.
Diluted EPS stood at ₹157.92 in FY2026, compared to ₹167.79 in FY2025.
Is Pfizer Undervalued
Pfizer Ltd. shares are currently trading at ₹4,914.60.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Pfizer Shareholding Pattern
Promoters continue to hold 63.9% of the company, unchanged over recent quarters.
As of June 2026, FIIs own 1.6% of the company — down from 2.6% a year earlier.
Domestic institutional investors (DIIs) held 17.8% as of June 2026, up from 17.1% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 63.9% | 1.6% | 17.8% | 16.6% |
| Mar 2026 | 63.9% | 2.8% | 16.9% | 16.4% |
| Dec 2025 | 63.9% | 2.7% | 17.1% | 16.3% |
| Sep 2025 | 63.9% | 2.6% | 17.1% | 16.4% |
Track quarterly shareholding changes for Pfizer Ltd. →
Pfizer Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2026, the total asset base came in at ₹49.22B, up 0.2% YoY from ₹49.11B.
Cash & ST Investments accounts for 63.2% of the total, ahead of Intangibles & Goodwill (11.0%) and Inventories (9.6%).
Capital structure: 85.4% equity, 1.4% debt, 13.2% operating liabilities. Over the year, debt is down 35.2% and equity is down 0.3%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 31.11B |
| Receivables | 1.82B |
| Inventories | 4.73B |
| Property, Plant & Equipment | 1.56B |
| Intangibles & Goodwill | 5.42B |
| Other Assets | 4.59B |
| Category | Value |
|---|---|
| Equity | 42.03B |
| Short-term Debt | 341.50M |
| Long-term Debt | 360.80M |
| Trade Payables | 2.16B |
| Other Liabilities | 4.33B |
Pfizer Stock Analysis
Here's the bottom line on Pfizer Ltd. (PFIZER) based on the latest available financials.
Revenue of ₹2,520 Cr in FY2026, up 10.4% year-over-year.
Long-term revenue has been compounding at 2.2% annually over 10 years.
The company is profitable, with a net margin of 28.7% and net income of ₹722 Cr.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Pfizer Ltd. includes three valuation models, decade-long financials, and insider activity.